Emergent BioSolutions closed on a new credit facility agreement with OrbiMed for a new $150 million term loan. The proceeds from the new term loan were used to repay all amounts outstanding under the previous term loan facility agreement with Oak Hill Advisors. Emergent also amended its asset-based revolving loan facility (ABL) with Wells Fargo, which now provides borrowing capacity of up to $50 million. Both the new term loan agreement and the ABL amendment extend maturities up to five years, through April 2031.
“We continue to push forward in strengthening our balance sheet and improving our financial flexibility to position Emergent for sustainable long-term growth,” Joe Papa, president and CEO of Emergent, said. “By refinancing our prior term loan facility and extending maturities, we expect to reduce our interest expense and bolster our cash position thereby allowing us to opportunistically deploy capital on value-creating strategic initiatives to advance our multi-year transformation plan.”
The new term loan agreement and amended ABL credit facility provide enhanced operational flexibility through less restrictive covenants, lower interest expense and increased ability to incur incremental debt to support business development opportunities.
New Debt Description
- Maturity of the new $150 million term loan has been extended to April 16, 2031 from Aug. 30, 2029.
- Maturity of the amended $50 million ABL has been extended to April 16, 2031 from Sept. 30, 2029.
- Interest expense on the new $150 million term loan has been reduced by 200 basis points annually.
- Additional capacity to incur incremental debt through a committed delayed draw term loan and expanded debt baskets.
